ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
Enhancing Treatment of Hepatitis C in Opioid Substitution Settings II (ETHOS II): A Partnership Project to Enhance Hepatitis C Care in Drug and Alcohol Clinics
Kirby Institute
6,000 participants
May 28, 2018
INTERVENTIONAL
Conditions
Summary
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
Eligibility
Inclusion Criteria5
- Participant has voluntarily signed the informed consent form;
- years of age or older;
- History of injecting drug use\*;
- Recent injecting drug use (previous six months) or currently receiving OST\*.
- These criteria will not apply for recruitment from residential rehabilitation centres
Exclusion Criteria1
- Nil
Interventions
Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
Locations(29)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03685045